Medical Developments International Limited · ASX:MVP
Medical Developments International — H1 FY2005 Earnings Presentation
15 slides from Medical Developments International's earnings presentation, Mar 1, 2005
Slide 1: Medical Developments International Limited Presentation March 2005
® Medical Developments International Limited (“MDI”) Presentation March 2005
Slide 2: Outline
Outline «= Summary « Financial Performance for Half Year « Operations Update “ = 2 = © c Sms o Z = a a iss G = S. 2 © es ® oO @ a ¢e) © =
Slide 3: Summary
Summary = EBITDA of $555k and NPAT of $117k in the first half of FY2005 * Nearly $700k invested in marketing & registrations to lay the foundations for growth - The registration programme continues to grow and is beginning to bear fruit with the recent registration in Pakistan. - Whilst the Penthrox
Slide 4: Financial Report for Half-Year ended December '04: Summary of Income Statement
Financial Report for Half-Year ended December ‘04: Summary of Income Statement © FY ’05 ja 2 $k % of sales © a Sms 2 Revenue 2850* & Hh Gross profit 1846 65.6 c Ee Operating expenses 1592 e Interest expense 94 a) a Profit before tax 196 6.9 Oo Tax expense 79 8 es) Net profit 117 44 ee = Note: * incl
Slide 5: Financial Report for Half-Year ended December '04
Financial Report for Half-Year ended December ‘04: Forecast revenue growth did not materialise largely because of transitional delays on new contracts and Research Laboratory sales of Penthrox™ remained on hold. Product Actual Sales Comment $k Penthrox™ 1498 Ambulance growth in line with forecast Re
Slide 6: The Penthrox sales cycle is typically lengthy
Operations Report for Half-Year ended December ‘04: Penthrox™ The Penthrox™ sales cycle is typically lengthy Typical Sales Cycle Training & Steps: Awareness Evaluation Trial* Approval Usage Purchase Protocols* Timeframe: 3-6 months 3-12 months 1-3 months 1-6 months ¢ >| + >! <4 >| 4 > MDI's strategy
Slide 7: MDI has Penthrox registered in Australia, New Zealand and Pakistan
Operations Report for Half-Year ended December ‘04: Penthrox™ MDI has Penthrox™ registered in Australia, New Zealand and Pakistan. Further registrations will likely occur in Q3 2005. © Country Filing Date Current Status Estimated Registration Date ja 2 Toe vs 2 Pacific Islands - Australia and/or NZ
Slide 8: Registration in developed markets typically takes two years or more
Operations Report for Half-Year ended December ‘04: Penthrox™ Registration in developed markets typically takes two years or more. Our registration efforts have focussed predominantly on the USA to date Registration Progress — Developed Countries = New Zealand & Australia ~ registration complete = U
Slide 9: Penthrox approval by mass disaster relief organisations
i = 2 & © c Sms o Z = a a iss G = S. 2 © o4 ® oO @ a ¢e) © = Operations Report for Half-Year ended December ‘04: Penthrox™ Penthrox™ is the ideal analgesic in mass disaster situations. MDI is seeking to have Penthrox™ approved by leading organisations in this field. = World Health Organisation: » Ap
Slide 10: Our marketing programme is extensive and continues to gather momentum
Operations Report for Half-Year ended December ‘04: Penthrox™ Our marketing programme is extensive and continues to gather momentum. With few exceptions, sales will only occur once registration has been completed. Typical Sales Cycle — Status of Marketing Efforts Training & A I Awareness Evaluation
Slide 11: MDI has made significant progress with the appointment of agents in target markets
Operations Report for Half-Year ended December ‘04: Penthrox™ MDI has made significant progress with the appointment of agents in target markets. kes Role S Country Status Sales Distribution S (3) New Zealand Appointed v v & Pakistan Appointed v v D iran Appointed ¥ ¥ S&S iraq Appointed v Y ay Afgha
Slide 12: MDI is providing significant in-market sales support
Operations Report for Half-Year ended December ‘04: Penthrox™ MDI is providing significant in-market sales support. = Technical Product Information = Product Information - Presentations - Papers - Flyers * Marketing Support - Agent training - Product samples - Marketing collateral - Conferences - Cu
Slide 13: MDI has identified attractive new markets of which hospitals will likely be the largest
oS = 2 = © c Sms o Z £ fy a iss G = S. o © es ® oO @ a ¢e) © = Operations Report for Half-Year ended December ‘04: Penthrox™ MDI has identified attractive new markets of which hospitals will likely be the largest. Sales will be incremental until critical mass is achieved. Hospitals Emergency Room Bu
Slide 14: Medical Equipment
Operations Report for Half-Year ended December ‘04: Medical Equipment MDI is in discussions with prospective distributors in numerous countries Prospective Markets UK Greece Malaysia USA Poland Qatar Germany Turkey Pakistan France Jordan lran Italy India Syria Spain Saudi Arabia Lebanon “ = 2 = © c
Slide 15: Operational Capacity
Operations Report for Half-Year ended December ‘04: Operational Capacity MDI is weil positioned to accommodate growth. " Penthrox™ production capacity doubled * Factory 8 refurbishment - Optimises Penthrox™ Inhaler and Peak Flow Meter assembly lines - Increases warehousing capacity - Increases space
Medical Developments International — H1 FY2005 Earnings Presentation on 6ix